The anti-tumor effect of IDH mutations is nullified by CDKN2A/B deletion, diminished with TP53 mutations or 1p/19q codeletions, and strongest with intact tumor-suppressor genes (Fig. S2 in Additional file 1). The gene discussed is TP53; the disease is neoplasm.